Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher to Supply Genentech with RNAi Tech for Drug Studies

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it will supply Genentech with RNAi technology for use in siRNA-based drug discovery research.
 
Under the agreement, Thermo Fisher Scientific will provide Genentech with siRNA design, stabilization, delivery, and related RNAi technologies from its RNAi Discovery and Therapeutic Services lab in Colorado.
 
The drugs Genentech is working on would silence expression of disease-related genes, which could help extend drug research efforts on targets that have so far not been successfully developed.
 
“Our work with Genentech will focus on developments that will enable in vivo target validation and potentially human therapeutic applications of RNAi technology,” Thermo Fisher Scientific VP of Global R&D Ian Jardine said in a statement.
 
Financial terms of the agreement were not released.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.